Frequently asked questions

We use a transparent 3-tier model (advanced, linear-regression, simple) plus an inherited tier, all documented on our methodology page. The most common reason a curve looks different here is that we apply a dose-scaling exponent for compounds whose peak concentration is known to be non-linear in dose — notably testosterone esters.

Because you’re dosing repeatedly. Half-life describes the decay of a single dose in isolation. With ongoing dosing, each new dose is added on top of residual drug, so the combined curve (a superposition) doesn’t drop to 50% after one half-life — the newest dose is still near its peak. This accumulation is what drives the approach to steady state.

Use our contact form with the compound name and, ideally, a peer-reviewed pharmacokinetic source. We prioritize adding compounds with reliable half-life and bioavailability data. Compounds without published PK data use our “inherited” or “simple” model tiers and are clearly labeled as approximate.

No. Our curves are simplified one-compartment approximations meant to illustrate patterns — accumulation, timing, peak-to-trough swings, and clearance. Real blood levels depend on genetics, body composition, injection technique, and organ function. Treat the curve as educational. Confirm any real-world decision with bloodwork.

When “Reference ranges” is toggled on in the chart header, a shaded green band shows the eugonadal total testosterone range (roughly 300–1000 ng/dL). The band is a population reference, not a personal target. Optimal levels within the band depend on symptoms, not just the number — and must be guided by bloodwork and a clinician.

When two or more compounds with a documented interaction are added to the plotter, a dismissible yellow banner appears below the chart explaining the concern. Our warnings surface known pairings from the literature — they are advisory and non-blocking. The absence of a warning does not mean a stack is safe; it means we have no flagged data for that pairing.

The PCT Planner takes the compounds you used and your last-dose date, estimates when each clears (using ≈5 × the half-life), identifies the latest clearance as the earliest sensible PCT start, and suggests a representative SERM (Nolvadex + Clomid) schedule from there. It is a harm-reduction estimation tool — actual PCT must be confirmed with bloodwork and clinical guidance.

Yes. Add the same compound multiple times using “Add compound,” then set different doses or schedules per row. For example, overlay 120 mg once weekly against 60 mg twice weekly to compare peak-to-trough ratios. Each row renders as a separate colored line.